"The economic and social costs of treating skin cancer are enormous. Some skin cancers will spontaneously regress while others will continue to grow and possibly which may be fatal," said lead researcher Dr Scott Byrne.
As yet, doctors have no clue as to why some skin cancers progress to fatality, while some regress on their own. The new study provides a clue by identifying a compound that is involved in fatal tumors.
The details of the study appear in the latest edition of the 'Immunology and Cell Biology' journal.